BioSpace News Archive

Aziyo Biologics, Inc., a commercial-stage regenerative medicine company announced that it has entered into a $25 million credit facility from SWK Holdings Corporation.

The U.S. Food and Drug Administration is providing an update on additional steps it has taken that will lead to more infant formula available in the U.S. under the agency’s recent increased flexibilities.

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), announced today that the Taiwan Food and Drug Administration (TFDA) has accepted the submission of a New Drug Application (NDA) for Xerava™ (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI).

Verona Pharma plc announced the pricing of its upsized public offering of 12,400,000 American Depositary Shares, each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share, at a price of $10.50 per ADS, for aggregate gross proceeds of $130.2 million before deducting underwriting discounts and commissions.

Belite Bio, Inc, a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, announced its financial results for the first six months ended June 30, 2022 and provided a general business update.